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Abstract
Background GENetics of mOyaMoyA (GEN-O-MA) project is a multicenter observational study implemented in Italy aimed at
creating a network of centers involved in moyamoya angiopathy (MA) care and research and at collecting a large series and bio-
repository of MA patients, finally aimed at describing the disease phenotype and clinical course as well as at identifying
biological or cellular markers for disease progression. The present paper resumes the most important study methodological
issues and preliminary results.
Methods Nineteen centers are participating to the study. Patients with both bilateral and unilateral radiologically defined MA are
included in the study. For each patient, detailed demographic and clinical as well as neuroimaging data are being collected.When
available, biological samples (blood, DNA, CSF, middle cerebral artery samples) are being also collected for biological and
cellular studies.
Results Ninety-eight patients (age of onset mean ± SD 35.5 ± 19.6 years; 68.4% females) have been collected so far. 65.3% of
patients presented ischemic (50%) and haemorrhagic (15.3%) stroke. A higher female predominance concomitantly with a
similar age of onset and clinical features to what was reported in previous studies on Western patients has been confirmed.
Conclusion An accurate and detailed clinical and neuroimaging classification represents the best strategy to provide the charac-
terization of the disease phenotype and clinical course. The collection of a large number of biological samples will permit the
identification of biological markers and genetic factors associated with the disease susceptibility in Italy.
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Introduction
Moyamoya angiopathy (MA) is a chronic cerebrovascular
condition characterized by a progressive stenosis of the
terminal part of the supraclinoid internal carotid arteries
(ICA) and their proximal branches associated with the
compensatory development of a fragile collateral vessels
network at the base of the brain (moyamoya vessels). MA
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is sub-classed in moyamoya disease (MMD) when MA is
bilateral and it is the sole disease manifestation, or
moyamoya syndrome (MMS) when MA is associated with
a well-defined acquired or genetic condition. MA occur-
ring unilaterally has been recently defined as unilateral
moyamoya disease (uMMD) [1].
The pathogenesis of MA is unknown. Anomalies in angio-
genesis and vasculogenesis, due to the detection of increased
cytokine and growth factor concentrations have been invoked
as potential disease mechanisms. Also genetic factors, given
the high familial rate and the ethnic differences, are believed to
be involved [1, 2].
The disease is rare with a prevalence being close to
3/100000 in East Asia and ten times less in Europe [3,
4]. MA mainly present intracranial hemorrhage or ische-
mic events in adults, whereas transient ischemic attacks
(TIAs) or ischemic strokes occur in most symptomatic
MA children [5]. Cerebral magnetic resonance imaging
(MRI) can show ischemic and haemorrhagic lesions even
in the absence of symptoms. The compensatory arterial
moyamoya network and the intracranial and extracranial
collaterals are best visualized on cerebral conventional
angiography, which is still considered as the gold standard
for MA diagnosis, according to established criteria [6, 7].
Besides, non-invasive imaging, such as MRI-angiography
(MRA) and computed tomography-angiography (CTA)
allowing visualization of steno-occlusive lesions, are used
for disease suspicion and follow-up monitoring [1].
Although no treatment of proven efficacy for reversing
the primary stenotic disease process in MA is currently
available, surgical revascularization has been shown to
improve cerebral blood flow to the affected hemisphere(s)
and prevent stroke [8–10]. A major issue is that the nat-
ural history of MA remains in most patients unpredict-
able. In addition, factors influencing the variable severity
of the clinical course are still unknown due to the limited
prospective literature data in non-operated cases [1, 11].
These data are much more limited in western populations
[12–15].
GENetics of mOyaMoyA (GEN-O-MA) project is a retro-
spective and prospective multicenter cohort study implement-
ed in Italy aimed at creating a network of centers involved in
MA care and research, and at collecting a large series of well
characterized patients. This network integrates the experience
of neurologists, neuroradiologists, neurosurgeons, biologists,
and geneticists in MA study and care. An accurate and de-
tailed clinical and neuroimaging classification will allow to
describe the disease clinical features and disease course in
Italy. Moreover, the collection of a large bio-repository of
biological samples will allow the identification potential bio-
logical markers and genetic factors associated with the disease
susceptibility. The present paper reports the most important
methodological issues of the network and preliminary results.
Patients and methods
Study design
The study was designed as a multicenter (prospective and
retrospective) observational cohort study across Italy. The
project is coordinated by the Cerebrovascular Unit of the
Fondazione IRCCS Istituto Neurologico Carlo Besta,
Milan, Italy. A strong collaborative relation with the
Neu r o r a d i o l og i c a l , Neu r o s u rg i c a l , a nd Ch i l d
Neuropsychiatric Unit and Developmental Neurology
Division of the same hospital and with other participating
centers allows a multidisciplinary collaboration leading to
an improved result achievement.
Two independent advisory boards (Prof. Med. Peter
Vajkoczy - Department of Neurosurgery, Charite
Universitätsmedizin, Berlin, Germany, and Prof. Med. E.
Tournier Lasserve - Department of Genetics, INSERM and
University Paris Diderot, Paris, France) with an extensive ex-
pertise in the field of MA have been announced to monitor the
study design and its reliability.
Ethical issues
The study design was approved by the Ethical Committee of
the Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy (report no. 12, 10/01/2014), and of each partici-
pating center. The study was also performed in accordance
with the World Medical Association Declaration of Helsinki.
Since it was designed as a pure observational study, pa-
tients underwent diagnostic procedures and received therapy
according to local practice and disease guidelines. Informed
written consent for study participation (for data and biological
samples collection) from all patients or their legal representa-
tives was mandatory for study inclusion.
Study population
The study population consists of a series of MA patients in-
cluding MMD, MMS, and uMMD (aged between 0 and
75 years), collected both retrospectively and prospectively
by the referring physicians of the centers participating in the
study. MAwas diagnosed according to established criteria: (1)
stenosis or occlusion at the terminal portion of the ICA and/or
the proximal portion of the anterior and/or middle cerebral
arteries (MCA), (2) abnormal vascular networks in the vicinity
of the stenotic lesions, and (3) a bilateral presence of these
findings [6, 16].
A first sample of 100 MA patients has been planned for
clinical and neuroradiological assessment. Patients are being
followed up for 2 years.
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Clinical data and biological samples collection
All included patients underwent a comprehensive work-
up including routine and autoimmunity blood tests,
neuro-ophtalmologic and electrophysiological evaluation,
Doppler/transcranial ultrasound, and neuroimaging ex-
aminations. A specific form implemented from current
literature has been developed for standardized data col-
lection. For each patient demographic and clinical data,
cerebrovascular risk factors, familial antecedents, racial
descents, current pathologies including immune diseases,
genetic syndromes, and pharmacological treatment have
been registered. Cerebrovascular events are classified
according to established standardized criteria (i.e., hem-
orrhagic, ischemic, lesion site) based on clinical features
and MRI findings. Also, other neurological clinical fea-
tures associated with MA including cognitive deficits,
seizures, and psychiatric disorders have been reported.
The use of these standardized forms, the centralized
data managing, and the control of quality assures a har-
monized and homogeneous data collection across the
participating centers. Clinical and neuroradiological data
collected within the GEN-O-MA project are summarized
in Table 1.
Blood and plasma samples from a subgroup of MA
patients and age-sex matched healthy and unrelated (ath-
erosclerotic patients) controls (HC and UC respectively)
are being collected. Cerebrospinal fluid CSF samples
and arterial specimens (MCA) of MA patients and UC
are being also gathered in a subset of patients undergo-
ing revascularization surgery.
Central neuroimaging analysis
The study provides for a centralized analysis of brain im-
aging studies, including contrast-enhanced magnetic reso-
nance imaging (MRI), MR angiography, perfusion weight-
ed imaging (PWI), digital subtraction angiography (DSA),
and transcranial doppler (TCD) ultrasound. For patients
who underwent brain MRI, sagittal T1-weighted spin echo,
axial T2-weighted turbo spin echo, coronal T2-weighted
FLAIR, diffusion weighted images (DWI), three-
dimensional time of flight phase contrast angiography,
and three-dimensional T1-weighted gradient echo se-
quences after gadolinium injection were recommended.
Two neuroradiologists (G.F and M.G.), with more than
7 years experience in neuroimaging visual rating and
blinded to clinical and biological/genetic data are carried
out quantitative and qualitative analyses, with reference to
the shape, size and location of infarctions, and the degree
of vessels stenosis-occlusion in the corresponding areas.
Perfusion weighted images (PWI) were acquired on a
1.5 T or 3 T units, to evaluate the regional relative cerebral
blood volume (CBV), relative mean transit time (MTT),
and time to peak (TTP) maps. A comprehensive digital
subtraction cerebral angiography (DSA) with selective
Table 1 Clinical and neuroradiological data collected
Collected data of GEN-O-MA project
Demographic (age, age at onset, sex, ethnicity, region of origin)
Clinical symptoms of qualifying event (TIA, stroke, ICH)
Stroke severity and disability scales (NIHSS, mRS, Karnofsky Scale)
Disease clinical manifestations (migraine, seizures, cognitive impairment, psychiatric disorders, ophthalmic disease)
Vascular and lifestyle risk factors (hypertension, diabetes, smoke, atrial fibrillation, ischemic cardiopathy, alcohol intake,
BMI > 25, radiotherapy, traumatic brain injury)
Autoimmune disorders and history of associated conditions or syndromic features (i.e., hormone disorders, Down syndrome,
Neurofibromatosis, Marfan syndrome, sickle cell disease, mental retardation, dysmorphisms, artery dissections, aneurisms, coagulation disorders)
Familial history for MA, cerebrovascular events, and other neurological manifestations (migraine, cognitive impairments, psychiatric disorders,
seizures, artery dissections, aneurisms)
Diagnostic workup (MRI, MRA, CTA, cerebral angiography, MRI perfusion, TCD)
Neuroimaging features (size and location of infarctions, degree of vessel stenosis-occlusion, regional relative CBV, MTT, and TTP, unilateral/bilateral
disease, modified Suzuki scoring, external carotid arteries collaterals, leptomeningeal collaterals, dilatation of the AChorA, PcomA/ICA ratio, cortical
and basal neovascularization, TCD mean flow in the middle cerebral arteries
Medical therapy (anti-aggregants, antiepileptic drugs, statins, other)
Surgical intervention (date, type, and side effects)
Follow-up (cerebrovascular events, neuroradiological assessment)
BMI, body mass index; CTA, computed tomography angiography; ICH, intracerebral hemorrhage; MA, moyamoya angiopathy; MRA, magnetic
resonance angiography; MRI, magnetic resonance imaging; mRS, modified Ranking Scale; NIHSS, National Istitute of Health Stroke Scale/Score;
TIA, transient ischemic attack; TCD, Transcranial Doppler ultrasound, CBV, cerebral blood flow; MTT, mean transit time; TTP, time to peak; AChorA,
Anteriori choroidal artery, PcomA, posterior communicating artery, ICA, internal carotid artery
Neurol Sci
catheterization of both internal and external carotid arteries
and the dominant vertebral artery was mandatory to eval-
uate collateral circulation for MA diagnosis for study in-
clusion. MAwas classified into the bilateral or unilateral type
according to the number of the involved distal internal carotid
arteries, observed on DSA. Disease severity was evaluated on
DSA by applying a modified Suzuki scoring [16] on cerebral
angiography findings, as follows: (0) no evidence of disease,
(1) mild-to-moderate stenosis around internal carotid artery
(ICA) bifurcation with absent or slightly developed ICA
MMD, (2) severe stenosis around the ICA bifurcation or oc-
clusion of either proximal anterior or MCA branches with
well-developed ICA MMD, (3) occlusion of both anterior
and MCA branches with well-developed ICA MMD (only a
few of anterior or MCA branches or both are faintly opacified
in antegrade fashion through meshwork of ICA MMD), and
(4) complete occlusion of both anterior and MCA branches
with absent or small amount of ICA MMD (without
opacification of either anterior or MCA branches in antegrade
fashion). [17] The external carotid artery collaterals were grad-
ed by using a 4-point scale: (0) no collateral distribution; (1)
slight collateral distribution, often with dilution; (2) small but
definite collateral supply; and (3) full collateral filling [18, 19].
In addition, we investigated the presence of leptomeningeal
collaterals (LMC) coursing from the posterior cerebral artery
(PCA) to the frontal, temporal or parietal lobes, the dilatation
of the anterior choroidal artery (AChorA), and the posterior
communicating artery (PcomA)/ICA ratio*.Cortical neovas-
cularization was defined as an enlarged winding of the distal
cortical arteries observed in the arterial DSA phase and cate-
gorized into anterior or posterior cortical neovascularization
depending on their sources (anterior vs. posterior circulation).
The degree of basal collaterals (BCs) was measured as the
ratio of the height from the carotid T-junction to the end of
the BC vessels and the height from the carotid T-junction to
the highest point of the imaginary superior sagittal sinus in the
antero-posterior projection × 100.
Transcranial Doppler (TCD) was performed using a
2-MHz transducer to acquire a continuous measurement
of mean flow velocities of the middle (M1-M2 segments
whenever available), anterior (A1 segment, whenever
available) and posterior (P1-P2 segments) cerebral arter-
ies, basilar artery, and intracranial vertebral arteries.
Moreover, an evaluation of vasomotor reactivity through
breath-holding technique from the middle cerebral artery
territory was bilaterally obtained in case of adequate
bone temporal windows [20, 21].
Experimental and genetic analysis
Blood, DNA, and CSF samples are being collected, when
available, to evaluate (1) number and function of circulating
endothelial progenitor cells (cEPCs), (2) levels of growth
factor within plasma and CSF, (3) MCA gene expression pro-
file of angiogenic and growth factors coding genes, and (4)
genetic factors associatedwith sporadic and familialMA cases.
Levels of cEPCs are being evaluated in whole blood sam-
ples by flow cytometry [22] and by flow-count fluorospheres
(Beckman Coulter s.r.l., Cassina De’ Pecchi, Italy).
CD45dimCD34 + CD133 + mononuclear cells will be con-
sidered as cEPCs. Moreover, in order to normalize the abso-
lute number of cEPCs on the number of circulating leuko-
cytes, a complete white blood cell (WBC) count is performed
applying the Advia 120 cell counter (Bayer, Leverkusen,
Germany). The % of cEPCs will be calculated as follows: %
cEPCs = no. cEPC × 100/(no. WBC/μl). The EPC function
will be assessed in vitro by isolating peripheral blood mono-
nuclear cells (PB-MNCs) as previously reported [23]. The cell
number for mm2 in vitro (cells/mm2) are being evaluated at
day 3, 7, 10, 17, and 31. Conditioned medium (CM) will be
used as stimulus for tube formation assays at day 7, and the
angiogenic EPC activity will be tested at day 17. Finally, real-
time (RT)-PCR experiments is being performed to evaluate
the gene expression of endothelial markers and angiogenic
growth factors in PB-MNCs and in EPC in vitro cultures
(HC versus MA).
MA plasma and available CSF samples will be tested for
cytokine and growth factor levels by using enzyme-linked im-
munosorbent assays (ELISA; R&DSystems,Minnesota, USA)
and Bio-Plex Assays (Bio-Rad Laboratories, Segrate, Italy).
Total RNA will be extracted from affected MCA and the
respective UC arteries followed by RT-PCR experiments using
the 96-Well RT2 Profiler™HumanAngiogenic Growth Factors
PCR Array (PAHS-072ZD) (Qiagen, Hilden, Germany).
For genetic analysis, genomic DNA are being obtained
from peripheral blood of patients and HCs using QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany). A two-step anal-
ysis has been planned including the genetic screening of
RNF213 gene of all patients, whereas exome sequencing anal-
ysis was intended for familial cases.
Fig. 1 Clinical center participating to the GEN-O-MA project: (1)
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano; (2)
ASST– Spedali Civili Di Brescia, Brescia; (3) ASST Papa Giovanni
XXIII, Bergamo; (4) Fondazione IRCCS Ca′ Granda – Ospedale
Maggiore Policlinico, Milano; (5) ASST Grande Ospedale
Metropolitano Niguarda, Milano; (6) Ospedale ASST Settelaghi Varese,
Varese; (7) ASST Ovest Milanese, Ospedale di Legnano; (8) Ospedale
Santa Maria Della Misericordia di Udine, Udine; (9) Arcispedale Santa
Maria Nuova, Reggio Emilia; (10) Nocsae Modena, Modena; (11)
Azienda Ospedaliera Universita’ Degli Studi di Padova, Padova; (12)
Clinica Neurologica Padova, Padova; (13) IRCCS Istituto Giannina
Gaslini, Genova; (14) Azienda Ospedaliera Universitaria Careggi,
Firenze; (15) Umberto I– Policlinico di Roma, Roma; (16) Policlinico
Universitario Campus Bio-Medico, Roma; (17) Ospedale Santa Maria
Della Misericordia, Perugia; (18) Ospedale Regionale San Salvatore,
L’aquila; (19) Ospedale di San Benedeto Del Tronto, San Benedetto
Del Tronto.
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Statistical data analysis
Before starting the analysis, a quality evaluation of all collect-
ed data will be performed and the validity of screening
procedures will be assessed. Data analysis will be carried out
centrally by the Coordinating Center using the full dataset.
The chi2 test will be applied to assess the significant differ-
ences between patients subgroups (i.e., MMD, MMS,
Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia
NOCSAE Modena, Modena
ASST Spedali Civili Di Brescia, Brescia
ASST Papa Giovanni XXIII, Bergamo
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Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano
ASST Grande Ospedale Metropolitano Niguarda, Milano
Fondazione IRCCS Ca’ Granda - Opsedale Maggiore Policlinico, Milano 
Ospedale ASST Settelaghi Varese, Varese
Lombardia
Emilia Romagna
IRCCS Istituto Giannina Gaslini, Genova
Liguria
Veneto
Clinica Neurologica Padova, Padova
Azienda Ospedaliera Università degli Studi 
di Padova, Padova
Ospedale di San Benedetto Del 
Tronto, San Benedetto Del TrontoUmbria
Ospedale Santa Maria della Misericordia, Perugia
Abruzzo Ospedale Regionale San Salvatore, 
L’Aquila
Azienda Ospedaliera Universitaria 
Careggi, Firenze
Toscana
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UdineFriuli-Venezia 
Giulia
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uMMD, or MA grading) with respect to the clinical and neu-
rological features as well as to the results of biological exper-
iments and genetic analysis. The independence of single pre-
dictive factors will be assessed by logistic regression analysis.
All analyses will be calculated using STATA 8.0 (StataCorp
LP, College Station, TX) and S-PLUS (Suite 44, Level 9, 88
Pitt Street Sydney New South Wales, Australia).
Results
Study centers
Nineteen centers effectively participated in MA patients
recruitment (Fig. 1). Although the recruiting period was
intended to start in January 2015, patient data collection
began almost 6 months later than the anticipated date due
to awaiting the local ethics committee approval.
Patients’ characteristics
Between January 2015 and July 2017, 98 MA patients
(MMD,MMS) mean ± SD age 35.5 ± 19.6 years were collect-
ed. Seventy-three (74.5%) were adults and 25 (25.5%) were
children. Mean age ±SD of the onset was 33.5 ± 19.8 years
and 67 (68.4%) were females. Mean NIHSS ±SD and mRS
±SD were 2.95 ± 3.24 and 0.70 ± 1, respectively.
Twenty-six cases (26.5%) presented high blood pressure,
25 (25.5%) hypercholesterolemia, 7 (7.1%) had diabetes,
while as expected, atrial fibrillation and cardiopathy were
present in 3.1% of our MA cases.
The index event was stroke in 64 (65.3%) cases (76.5%
ischemic and 23.4% hemorrhagic) and TIA in (12.2%) cases.
The number of cases for center is represented in Fig. 2. Sixty-
four (65.3%) patients exhibited only one cerebrovascular
event at the inclusion time. Only 20 patients referred > 2 ce-
rebrovascular event in the past.
Forty-five patients (45.9%) presented headache/migraine, 29
(29.6%) seizures, 21 (21.4%) cognitive impairments, 20 (20.4%)
psychiatric disorders, and 10 (10.2%) ophthalmic disorders.
Bilateral involvement was identified in 60 (61.2%) pa-
tients, and 41 (41.8%) patients underwent surgical
revascularization.
Familial history for MA was present in 4 (4.1%) of the
patients whereas familial history for stroke/TIA was present
in 33 (33.7%) of the cases. Preliminary GEN-O-MA clinical
data and reported literature from Caucasian and Asian MA
patients are outlined in Table 2.
Moyamoya biorepository
For cEPC analysis whole blood of 16 MA, 20 HC, and 8 UC
was collected till date, whereas 8 MA versus 5 UC affected
arteries were analyzed for RT2 Profiler™ Human Angiogenic
Growth Factors PCR Array.
To date, 27 plasma and 15 CSF samples along with
30 MA, 20 HC, and 8 UC DNA samples have been
collected.
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Fig. 2 Number of patients for center participating to the GEN-O-MA project
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Discussion
The exact phenotype and clinical history of MA are still
poorly defined. The remarkable disease variability and the
small size reported in studies addressing the disease path-
ogenesis along with inadequate data on brain imaging
follow-up limit a clear definition of the disease course
and the identification of factors influencing MA progres-
sion [28]. Particularly, data on MA in Western countries,
hereby mostly in Europe are lacking. Although a similar
phenotype between the US and European patients has been
described, the rarity of the disease in Europe, the lack of
systematic studies, the multi-ethnic origin, and the hetero-
geneity of the studied cohorts further impair the acquisition
of clear information on clinical feature and disease pro-
gression in Europeans [12–15, 28–32].
The identification of clinical and imaging predictors is
necessary to improve a prognostic evaluation and develop
innovative therapeutic approaches. Moreover, pathophys-
iological mechanisms driving MA are largely unknown.
Based on the existence of familial cases and the observa-
tion of a pronounced ethnicity effect, a genetic contribu-
tion is likely presumed [1, 11, 14, 28]. Strong association
between MA and a RNF213 variant (R4810K) has been
found in the East Asian population in around 90% of
familial and 70% of sporadic cases. Despite preliminary
reports excluded an association between this gene and
MA in Caucasians [30]. Recently, rare RNF213 variants
have been reported also in some European cases, particu-
larly with early onset and familial MA [31]. Additional
familial cases of MA associated with facial dimorphisms
and achalasia respectively were recently associated muta-
tions in BRCC3 deubiquitinase and GUCY1A3 gene,
encoding the major nitric oxide receptor in vascular
smooth muscle cells [32, 33]. However, these genes are
not able to completely explain MA pathogenesis, and the
genetic background of MA remains still not identified.
Several studies reported an overexpression of pro-
angiogenic factors in the CSF, blood, or tissue samples of
MA patients supporting the hypothesis that an unbalance of
these factors may contribute to an impaired angiogenic and
vasculogenic mechanisms leading to the characteristic vessel
fragility [2, 34].
Poor understanding of the disease determinants limited
so far advances in the clinical care and the development
of innovative and personalized treatment. Until date, no
Table 2 Preliminary clinical data of GEN-O-MA vs. European and Asian MA patients
Caucasian patients Asian patients
Demographic characteristics
Clinical features GEN-O-MA European [12, 15] American [24, 25] Chinese [5] Japanese [26] Korean [27]
(n = 98) (n = 153) (n = 61) (n = 7473) (n = 94) (n = 470) (n = 941) (n = 175)
Age at onset 33.5 ± 19.8 35.8 ± 14.86 31.5 ± 17.9 – 34.5 36.8 – 42.2 ± 11.3
(mean ± SD; year)
Female:male 2.2:1 2.9:1 4.5:1 2.2:1 2.6:1 1:1 1.98:1 1.57:1
Adults 74.5% 83.7% 83.6% 70.1% 100% 100% – 100%
Children 25.5% 16.3% 16.4% 29.9% 0% 0% – 0%
Index event characteristics
Stroke 65.3% – 63.9% 18.1% 73.4% 26.8% 41% 94.3%
Ischemic 50% 81% 50.8% 11.7% 57.4% – 20% 45.1%
Hemorrhagic 15.3% 8.5% 13.1% 6.4% 16.0% 20.4% 21% 54.9%
TIA 11.2% – 6.6% 34.0% 34% 41.1% 46% –
Other symptoms/signs
Headache 45.9% 3.9% 11.5% – 21.3% 9.6% 6% 29.7%
Seizures 29.6% 1.3% 4.9% – – 0.9% 4% 2.9%
Psychiatric disorders 20.1% – – – – – – –
Cognitive impairment 22.4% 1.3% – – 5.3% – – 5.1%
Ophthalmic diseases 36.4% – – – – – – 9.1%
Autoimmune diseases 16.3% – – – 22.3% – – –
Anatomic extent of moyamoya
side
Bilateral 61.2% 77.8% – – 86.2% 88.9% – –
BMI, body mass index; MA, moyamoya angiopathy; NIHSS, National Institute of Health Stroke Scale/Score; TIA, transient ischemic attack
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treatment has been identified to impair or slow the devel-
opment of stenotic process and fragile collaterals. The
direct or indirect revascularization surgery is considered
as the best therapeutic option to reduce the occurrence of
cerebrovascular events [11]. Although a recent meta-
analysis has confirmed the surgical revascularization to
prevent recurrent strokes in adult MMD patients, the
risks, benefits, and indications for surgery are still uncer-
tain and influenced by the retrospective design of most
included studies [10]. Moreover, the differences in the
selection of patient cohorts, diagnostic steps, surgical
techniques, related to the clinical experience of single
center limit the relevance of the available data. In sum-
mary, controlled trials prospectively analyzing the effica-
cy of different treatment strategies, by applying standard-
ized clinical assessments, are largely needed [11].
The GEN-O-MA project is, to our knowledge, the first
Italian Network and one of the largest Europeans studies
[12–15] published so far. The objective of this network, which
is integrated with other large European clinical centers in-
volved in MA study, is to describe the clinical phenotype
and identify disease progression markers of MA by applying
a careful clinical and neuroradiological evaluation.
Secondarily it is aimed at understanding the pathophysiology
of MA by applying a translational biological approach.
At a preliminary analysis of our MA series, although
the comparison with previous European and American
series is difficult, due to the lack and incompleteness of
previously collected data, we confirmed a similar age of
onset and the higher female predominance, with a
female/male ratio more comparable to the German and
American [12, 24, 25] rather than to the Finnish popula-
tion. The occurrence of ischemic and hemorrhagic stroke
and clinical features frequency was alike, except for a
modest increase rate of headache and seizures [12, 15,
25] (Table 2).
Our study has some important strength points: (1) it is a
multicenter study with a systematic and standardized recruit-
ment, (2) it permits a careful phenotyping by applying a
detailed questionnaire and a standardized qualitative and
quantitative characterization based on imaging data, and (3)
it is characterized by an innovative experimental approach,
including the evaluation of biological and genetic markers by
analyzing affected tissue samples. The correlation between
clinical and biological data as well as the direct analysis of
affected vessel specimens makes our approach highly prom-
ising [34].
The principal limitation of the study may be the insuf-
ficient sample size, due to the high analysis costs, which
may impair the understanding the significance of disease
progression markers and the role of rare variants with
very small effect sizes and weak gene–environment
interactions.
However, a collaborative effort allowing to collect a large
clinical dataset as well as DNA of MA patients, the GEN-O-
MA project is expected to provide novel data on genetic
susceptibility of MAwithin the Italian and/or European pop-
ulation. Due to the large cohort of Caucasian patients, strat-
ified by specific subclasses, our study allows the identifica-
tion of individuals with a potential risk for the development
of MA. [23]. The identification of phenotypes at-risk and/or
specific biological players driving the disease may improve
our ability to specify the disease prognosis for individual
patients and to develop personalized intervention/treatment
options.
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